Pirfenidone: a potential new therapy for restrictive allograft syndrome?

Am J Transplant. 2013 Nov;13(11):3035-40. doi: 10.1111/ajt.12474. Epub 2013 Sep 18.

Abstract

This case report describes the evolution of pulmonary function findings (FVC, FEV1 and TLC) and CT features with pirfenidone treatment for restrictive allograft syndrome following lung transplantation. Furthermore, we herein report hypermetabolic activity on (18) F-FDG PET imaging in this setting, which could indicate active fibroproliferation and pleuroparenchymal remodeling. These findings may warrant further investigation.

Keywords: Fibrosis; lung transplantation; pirfenidone; restrictive allograft syndrome.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allografts
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Emphysema / complications
  • Emphysema / surgery*
  • Fluorodeoxyglucose F18
  • Humans
  • Lung Transplantation / adverse effects*
  • Male
  • Middle Aged
  • Positron-Emission Tomography
  • Postoperative Complications / drug therapy*
  • Postoperative Complications / etiology
  • Pulmonary Fibrosis / complications
  • Pulmonary Fibrosis / surgery*
  • Pyridones / therapeutic use*
  • Radiopharmaceuticals
  • Syndrome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Pyridones
  • Radiopharmaceuticals
  • Tumor Necrosis Factor-alpha
  • Fluorodeoxyglucose F18
  • pirfenidone